Espinoza-González NA, Herz-Ruelas M, Ocampo-Candiani J, González-Soto R

Language: Spanish
References: 38
Page: 405-414
PDF size: 134.84 Kb.

ABSTRACT

The histologic and immunologic findings on psoriasis have led to the development of biologic therapies for its treatment. Biologic therapies are classified according to their structure as recombinant human proteins, monoclonal antibodies, and fusion proteins. Currently there are five biological drugs approved by the Food and Drug Administration for the treatment of psoriasis; however research studies are being performed to implement a few others. It is important to be familiarized with biological drugs, understand their mechanisms of action, and their adverse effects in order to be able to provide patients the most adequate therapeutical alternative. Advances in biotechnology provide new strategies that act on the immune system. The clinical experience using biological therapies in dermatology is relatively limited and there is a need to define which patients are candidates to receive these drugs. The combination of biologic treatments with traditional drugs needs further research since this could enhance their benefits, limit their toxicity, and reduce costs.

REFERENCES

1. Christophers E, Mrowietz U. Epidermis: disorders of persistent inflammation, cell kinetics, and differentiation. En: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fizpatrick’s dermatology in general medicine. United States: McGraw-Hill; 2003. p. 407-425.

2. Arenas R. Atlas de dermatología. Diagnóstico y tratamiento. Tercera edición. México: McGraw- Hill; 2005.

3. Lomholt G. Prevalence of skin diseases in a population; a census study from the Faroe Islands. Dan Med Bull 1964;11:1-7.

4. Farber EM, Nall ML. Epidemiology: natural history and genetics. En: Roenigk HH, Maibach HI, editors. Psoriasis. New York: Marcel Dekker; 1998. p. 107-158.

5. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26(4):314-20.

6. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352(18):1899-1912.

7. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46(1):1-23.

8. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48(1):68-75.

9. Ghoreschi K, Röcken M. Immune deviation strategies in the therapy of psoriasis. Current drug targets. Inflammation & Allergy –Drug Targets 2004;3(2):193-198.

10. Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005;4(1):19-34.

11. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139(12):1627-1632.

12. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 ;349(21):2014-2022.

13. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003;49(2 Suppl):S112-S117.

14. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357 (9271):1842-1847.

15. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46(6):886-891.

16. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144(3):587-589.

17. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41(7): 449-452.

18. O’Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002;138(5):644-648.

19. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol. 2002;138(5):686-688.

20. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005;183(4):205-208.

21. Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003;2(4):375-377.

22. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 2004;17(5):427-431.

23. Hodak E, David M. Alefacept: a review of the literature and practical guidelines for management. Dermatol Ther 2004;17(5):383-392.

24. Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345(4):248-255.

25. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139(6):719-727.

26. Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005;45(3): 286-298.

27. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138(5):591-600.

28. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290(23):3073-80. Erratum in: JAMA 2004; 291(9):1070.

29. Gottlieb AB, Hamilton T, Caro I. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006;54(4 suppl 1):S154-S163.

30. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003;49(2 Suppl):S98-104.

31. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349(21):2004-2013.

32. Gladman DD. Psoriatic arthritis. Dermatol Ther 2004;17(5):350-363.

33. Kincaid L. Psoriasis: TNF-alpha inhibitors and beyond. Drug Discov Today 2005;10(13):884-886.

34. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2002;24(6):371-391.

35. Walsh S, Shear N. Psoriasis and the new biologic agents: interrupting the T-AP dance. CMAJ 2004;170(13).

36. Sitaraman SV, Gewirtz AT. Oprelvekin. Genetics Institute. Curr Opin Investig Drugs 2001;2(10): 1395-400.

37. Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis Clin Immunol 2004;111(1):28-37.

38. Stebbins WG, Lebwohl MG. Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther 2004;17(5):432-440.